A paper by the Health and Social Care Committee had called on the Home Office not to confiscate cannabis products from parents of sick children.
It reports: “We are deeply sympathetic to families who want to be able to use medicinal cannabis to treat their children and who have seen individual benefit but are unable to obtain the product here in the UK.
“There needs to be a sense of urgency to explore the potential of medicinal cannabis in these conditions so that there is a robust research base on which to base future clinical decisions. We also call on the Government to desist from confiscating prescribed medicinal cannabis obtained overseas under specialist supervision.”
The paper also blames a lack of research for many products remaining unlicensed:
“There is potential medicinal benefit to cannabis-based products but the gaps in the research base mean that we do not know where this sits alongside other therapies.
“The Government should focus efforts in facilitating research especially in those areas where there is greatest patient need, as in the case of children with intractable epilepsy. We heard arguments that the small numbers of patients makes it difficult to conduct double blind RCTs but the Chief Medical Officer argued that if treatments are highly effective then this can be demonstrated with smaller numbers and that trials can be discontinued early in order that all participants can benefit.
“The UK needs to do more to learn from international best practice. We reiterate the importance of the UK being able to take part in multi-centre international research and post marketing surveillance. Some have argued that double blind RCTs are inappropriate for cannabis research but we do not support making an exemption for this class of medicines.”
A spokesperson for the Academy for Medical Cannabis, which aims to educate healthcare professionals in the UK on medicinal cannabis, said: “More awareness is needed of the scope of existing evidence, and of the breadth of available global clinical experience. We commend the calls to remove barriers to more high-level research.”
These barriers include product manufacturers obstructing clinical trials, according to the report.
MPs note that certain pharmaceutical companies are not making products available for clinical trials.
They urge the Department of Health to “name and shame” companies obstructing trials into cannabis products “as a matter of urgency”.
The report also claims that the government “failed to communicate” the lack of research-based evidence to the public, prompting a backlash against doctors from people eager to access the benefits of medical cannabis.
It concludes: “The reality of the change in law was that medicinal cannabis products were rescheduled, which allowed them to be prescribed. However, most medicinal cannabis products are unlicensed, and therefore remain governed by a restrictive prescribing process. The Government failed to communicate this point, and unduly raised the hopes and expectations of patients and their families.
“The Home Office, Department of Health and Social Care and NHS England should consult relevant patient and professional organisations and form a communications plan to relay clear information to patients and the wider public about the availability of CBPMs and the need for further research.”
Read the report in full here.
CBD might help people quit using cannabis – study
Prescription-grade CBD, which is much stronger than commercially available CBD, helped people quit cannabis, according to a new study published in the journal Lancet Psychiatry.
Researchers recruited 82 people who had been diagnosed with moderately severe or severe cannabis use disorder, which is described as continued use of cannabis despite impaired psychological, physical, or social functioning.
All of the participants expressed a desire to cut down their cannabis use, and had tried to quit in the past.
They were either given prescription-grade CBD capsules – either 200mg, 400mg or 800mg of CBD – or placebo pills, to take every day for four weeks. T
They all also had a series of counselling sessions aimed at helping them stop using cannabis.
The researchers found that daily CBD doses of 400 and 800 milligrams both reduced the participants’ cannabis intake.
The study, which was funded by the Medical Research Council, could help more people quit using cannabis in an ‘acceptable treatment format,’ Tom Freeman, psychopharmacology researcher at the University of Bath and co-author of the study, told Inverse.
Research has found that almost half of those who quit cannabis experience some withdrawal symptoms, which can include irritability, depressed mood, nausea, vomiting, aggression and disrupted sleep.
There are currently no treatments available for prescription that are deemed safe and effective.
Study shows medical cannabis has potential to kill cancer cells
New findings have raised the prospect of medical cannabis being used as a cancer treatment, rather than just as a relief medication.
Laboratory tests in Austraia have shown that a modified form of medicinal cannabis can kill or inhibit cancer cells without impacting normal cells.The significant outcome follows three years of investigations by cancer researcher Dr Matt Dun in collaboration with biotech company Australian Natural Therapeutics Group (ANTG), which produces a cannabis variety containing less than 1 per cent THC (tetrahydrocannabinol) – the psychoactive component commonly associated with marijuana.
The plant, known as ‘Eve’, has high levels of the compound cannabidiol (CBD).
The study was conducted at the University of Newcastle and Hunter Medical Research Institute
“ANTG wanted me to test it against cancer, so we initially used leukaemia cells and were really surprised by how sensitive they were,” Dr Dun says.
“At the same time, the cannabis didn’t kill normal bone marrow cells, nor normal healthy neutrophils [white blood cells].
“We then realised there was a cancer-selective mechanism involved, and we’ve spent the past couple of years trying to find the answer.”
The Dun team has run comparisons between THC-containing cannabis, and cannabis lacking THC but with elevated levels of CBD. They found that, for both leukaemia and paediatric brainstem glioma, the CBD-enriched variety was more effective at killing cancer cells than THC varieties.
In a recent paper entitled “Can Hemp Help?”, released by international journal Cancers, Dr Dun and his team also undertook a literature review of over 150 academic papers that investigated the health benefits, side-effects, and possible anti-cancer benefits of both CBD and THC.
“There are trials around the world testing cannabis formulations containing THC as a cancer treatment, but if you’re on that therapy your quality of life is impacted,” Dr Dun says.
“You can’t drive, for example, and clinicians are justifiably reluctant to prescribe a child something that could cause hallucinations or other side-effects.
“The CBD variety looks to have greater efficacy, low toxicity and fewer side-effects, which potentially makes it an ideal complementary therapy to combine with other anti-cancer compounds.”
The next phase for the study includes investigating what makes cancer cells sensitive and normal cells not, whether it is clinically relevant, and whether a variety of cancers respond.
“We need to understand the mechanism so we can find ways to add other drugs that amplify the effect, and week by week we’re getting more clues.
“It’s really exciting and important if we want to move this into a therapeutic,” Dr Dun adds, stressing that CBD-enriched cannabis isn’t yet ready for clinical use as an anti-cancer agent.
“Hopefully our work will help to lessen the stigma behind prescribing cannabis, particularly varieties that have minimal side-effects, especially if used in combination with current standard-of-care therapies and radiotherapy.
“Until then, though, people should continue to seek advice from their usual medical practitioner.”
The study was funded by ANTG and HMRI through the Sandi Rose Foundation.
“We are very pleased to see three years of collaboration with UON and HMRI deliver such exciting findings in the fight against cancer. ANTG remains committed to its patient-centric mission of understanding the massive therapeutic potential of medicinal cannabis,” Matthew Cantelo, CEO, Australian Natural Therapeutics Group, said.
“We thank Matt Dun and the team for such encouraging insights into anti-cancer properties of our Australian grown CBD strain, Eve. We are looking forward to moving forward to the next stage of the study and continuing to develop effective, safe and consistent cannabis medicines for Australian patients.”
Dr Matt Dun is from the University of Newcastle, researching in conjunction with the Hunter Medical Research Institute (HMRI) Cancer Program. HMRI is a partnership between the University of Newcastle, Hunter New England Health and the community.
How CBD is helping women with endometriosis
Women around the world are increasingly using CBD to deal with the symptoms of endometriosis – a much misunderstood and misdiagnosed condition. Cannabis Health finds out more.
Endometriosis is the second most common gynecological condition in the UK, affecting around one in 10 UK women – although frequent misdiagnosis and a lack of understanding means this figure may be higher.
It happens when tissue similar to the lining of the womb starts to grow in other places, such as the ovaries and fallopian tubes, which then reacts to the menstrual cycle each month and also bleeds.
However, there is no way for this blood to leave the body, causing inflammation, pain and the formation of scar tissue.
Nobody knows what causes it, or why some women suffer and others don’t, and symptoms, including pain in the lower abdomen and back, nausea, intense fatigue and infertility, can be debilitating.
According to Endometriosis UK, it takes an average of seven and a half years from onset of symptoms to get a diagnosis, and the condition costs the UK economy £8.2bn a year in treatment, loss of work and healthcare costs.
There is currently no cure, and treatment is limited to painkillers, hormonal contraception, or surgery to cut away the scar tissue. In more severe cases, the only option may be a full hysterectomy to remove part or all of the affected organs.
But could there be another way? More and more women are turning to CBD to ease their symptoms, and the results are encouraging.
Charlotte Nichols, managing director of North East of England-based PR firm Harvey & Hugo, has been using a CBD oil for a couple of months, and has already noticed a difference in her symptoms.
She explained: “I was diagnosed with endometriosis in 2017 but I’d been suffering with it for three years before that; it took that long to diagnose as it was just put down to ‘just’ painful periods.
“I had surgery to remove it but still struggled with infertility, until I finally got pregnant in 2018. The symptoms disappeared while I pregnant and breastfeeding but then came back with a bang since – I’d forgotten how awful it was.”
After researching how CBD could help, Charlotte began taking the oil in June 2020, and the results have been significant.
She said: “While the CBD doesn’t stop the pain completely, it definitely helps take the edge of the symptoms.
“Stress and lack of sleep both make my symptoms worse, and the oil has definitely helped with this, helping me relax and dramatically improving my sleep.
“I’ve also found that the CBD has improved my mood, as feeling so rubbish all the time was getting me down. That might be the effect of the oil itself, or simply because it’s alleviating the symptoms – either way, it’s making me feel more like myself again.”
While using CBD as a painkiller is nothing new, experts believe that its use for endometriosis may be down to more than simple pain relief.
Research has found that cannabinoids also help by:
- Stopping the endometrial cells from multiplying
- Preventing them from migrating to other parts of the reproductive system
- Stopping the blood supply to the lesions – effectively starving them of the nutrients they need to grow
- Regulating nerve growth
- Reducing inflammation
- Modulating the immune response
- Desensitising the nerves that transmit pain.
In fact, some scientists believe that dysfunction in a woman’s endocannabinoid system – the molecular system responsible for regulating and balancing processes in the body, including immune response – may be behind endometriosis.
Dr Michele Ross, CEO of Infused Health, explains: “Reduced function of the endocannabinoid system leads to the growth of endometriosis throughout the body, and more pain.”
CB1 cannabinoid receptors mediate the pain from endometriosis and, according to a 2010 study, are present in the cells that supply nerve impulses to the endometrial growth.
However, the endometrial cells of women with endometriosis have been found to have a lower expression of CB1 receptors — so activating the few that are expressed is even more important for those in pain.
Whatever the science behind it, women like Charlotte are just pleased to finally have a natural product to alleviate their symptoms.
“I much prefer taking CBD to other painkillers, as I’m very aware of what I’m putting into my body and, as far as I’m concerned, the more natural the better,” she says.
“At the moment I’m just using the oil; I haven’t tried any other products, like the balms or lotions, but I’m going to look into it.
“I also find that exercise, intermittent fasting, avoiding alcohol and cutting down on sugar really helps my symptoms, in combination with the CBD. It’s been a long road, with a lot of trial and error along the way, but I’m so glad to finally feel in control of my body again.”
- CBD might help people quit using cannabis – study
- Study shows medical cannabis has potential to kill cancer cells
- How CBD is helping women with endometriosis
- From alcoholic wine to cannabinoids: one teetotaller’s journey to CBD
- Big plans afoot at Halifax HQ
- Cannabis is common ground for boomers and millennials – study
Feature1 month ago
Medical cannabis could help long-term effects of COVID-19, says David Nutt
Case Studies5 months ago
CBD oil and fibromyalgia – a case study
News2 weeks ago
Microdosing THC lessens chronic pain – study
Feature2 weeks ago
Enterprise and education – a CBD story
News2 weeks ago
NHS lines up cannabis medicine manufacturing
Industry1 week ago
From alcoholic wine to cannabinoids: one teetotaller’s journey to CBD
News2 weeks ago
Choosing the right CBD for you
Feature3 weeks ago
CBD and sport sponsorship – the perfect match